The development of targeted agents, e.g., ivosidenib and enasidenib for patients with IDH1/2 mutated AML, and gilteritinib for patients with FLT3-mutated AML, has also offered options to older, unfit patients who would have otherwise been offered BSC (12). The gene discussed is FLT3; the disease is acute myeloid leukemia.